Loading
There are far more possible drug combinations than can ever be tried in patients. Test thousands on living samples of real tumours, then feed only the winners into adaptive trials.
The combination space of approved and investigational cancer drugs is astronomically large; combinations reach the clinic through intuition and commercial convenience. Functional precision medicine (ex vivo drug testing on patient cells, EXALT trial in haematological malignancies) and high-throughput organoid screening make empirical combination discovery on patient material feasible. The proposal is an integrated pipeline: standardised ex vivo combination screens on fresh samples from trial participants, machine learning to prioritise synergistic and resistance-preventing pairs, and a standing Bayesian platform trial that adds and drops combination arms based on pipeline output.
Shares Patient-derived organoids to pick ADC payloads, Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Patient-derived organoids to pick ADC payloads, AI-driven drug & target discovery, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Lab models that fail to predict what happens in patients, Too many combinations to test, Colorectal cancer.
Shares Patient-derived organoids to pick ADC payloads, Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Patient-derived organoids to pick ADC payloads, Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients, Too many combinations to test.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Basket, umbrella, and platform trials, Too many combinations to test.